BRAF and cancer: Preclinical study of trametinib showed efficacy against cancer cells with either BRAF or RAS mutations and even on cancer cells with neither BRAF nor RAS mutations [8]; therefore, cancers without BRAF mutations are included in clinical trials of trametinib.